RecruitingNot ApplicableNCT05209568
Immune Responses to Gluten
Changes in Serum IL-2 Levels Following a Single Oral Dose of Gluten
Sponsor
Boston Children's Hospital
Enrollment
400 participants
Start Date
Jan 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Eligibility
Min Age: 2 YearsMax Age: 101 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Gluten Powder for people with celiac disease, celiac disease in children, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 2 Years to 101 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTGluten Powder
Single oral dose of gluten powder
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05209568
Related Trials
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800285 locations
Tissue Destruction and Healing in Celiac Disease
NCT056800123 locations
Evaluation of Patients With Gastrointestinal Disease
NCT050413741 location
Screening for Disorders of Lipid Metabolism and Familial Hyperlipidemia in Children and Adolescents With Increased Cardiovascular Risk Due to Chronic Diseases Such as Congenital Heart Disease, Chronic Inflammatory Bowel Disease, Celiac Disease and Rheumatic Disorders
NCT077164881 location
Study of DONQ52 in Active Celiac Disease
NCT0723933662 locations